Imperial College London
Portrait Picture

Dr Peter M George

Faculty of Medicine, National Heart & Lung Institute

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

p.george

 
 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{George:2020:10.1016/S2213-2600(20)30225-3,
author = {George, PM and Wells, AU and Jenkins, RG},
doi = {10.1016/S2213-2600(20)30225-3},
journal = {The Lancet Respiratory Medicine},
pages = {807--815},
title = {Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy},
url = {http://dx.doi.org/10.1016/S2213-2600(20)30225-3},
volume = {8},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215000 deaths. The symptoms associated with COVID-19 are diverse, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome. The major risk factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF), namely increasing age, male sex, and comorbidities such as hypertension and diabetes. However, the role of antifibrotic therapy in patients with IPF who contract SARS-CoV-2 infection, and the scientific rationale for their continuation or cessation, is poorly defined. Furthermore, several licensed and potential antifibrotic compounds have been assessed in models of acute lung injury and viral pneumonia. Data from previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic consequences following SARS-CoV-2 infection. Antifibrotic therapies that are available or in development could have value in preventing severe COVID-19 in patients with IPF, have the potential to treat severe COVID-19 in patients without IPF, and might have a role in preventing fibrosis after SARS-CoV-2 infection.
AU  - George,PM
AU  - Wells,AU
AU  - Jenkins,RG
DO  - 10.1016/S2213-2600(20)30225-3
EP  - 815
PY  - 2020///
SN  - 2213-2600
SP  - 807
TI  - Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
T2  - The Lancet Respiratory Medicine
UR  - http://dx.doi.org/10.1016/S2213-2600(20)30225-3
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000558867100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S2213260020302253?via%3Dihub
VL  - 8
ER  -
Download